A
Indication details
- Control Arm
- Placebo
- Therapeutic Indication
- Adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older.
- Tumour Type
-
Skin Cancers
- Tumour Sub-type
- Cutaneous Melanoma
- Tumour Stage
- Adjuvant
- Trial Name
- CHECKMATE-76K
- NCT Number
- NCT04099251
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approval October 2023
Primary Outcome(s)
- Primary Outcome(s)
- RFS
- Evaluated Outcome
- RFS
- Form(s)
- Form 1
Outcome Data
- OS Control
- OS not reported (immature)
- RFS Control
- 12 months 79.4%
- RFS Gain
- 9.60%
- RFS HR
- 0.42 (0.30-0.59)
Adjustments
- QoL Comment
-
Not qualified for an ESMO-MCBS credit
Score (after adjustments)
- Curative score
-
A
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 403
- Scorecard version
- 1
- Issue date
- 20.11.2023